GALECTIN THERAPEUTICS INC — Director's Dealing 2015

Jul 8, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2014-09-23

Reporting Person: OMENN GILBERT S (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	29009	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A 12% Convertible Preferred Stock	$		Common Stock (50000)		Direct

Footnotes

F1: Each share of Series A 12% Convertible Preferred Stock is convertible into one-sixth of a share of Issuer's common stock at a conversion price of $1.00 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) automatically if the Issuer's common stock is quoted at or above $18 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of Issuer's common stock is in effect (subject to certain monthly volume limits). The shares of eries A 12% Convertible Preferred Stock do not expire.